This CE activity is intended for hematologic oncology clinicians who provide CAR-T therapy for individuals with aggressive B-cell lymphomas.

After completing this CE activity, the participant should be better able to:

• Assess the clinical implications of recent and emerging safety and efficacy data for CAR-T therapies
• Evaluate the implications of recent and emerging data for referring clinicians
• Respond to common questions from and misperceptions of referring clinicians
• Collaborate with the inter-professional team to facilitate logistics and access for referred patients
• Plan strategies to participate in effective shared care with referring clinicians

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.   Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

EACCME® Credit
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (EACCME®) should contact the UEMS (www.uems.eu).

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 0.3 contact hours in the area of pharmacology.

Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0007322-9999-22-058-L01-P

Type of Activity:  Knowledge

Physician Associate  Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2022 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology.